Publications in collaboration with researchers from University of Lille Nord de France (19)

2023

  1. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

    Chest, Vol. 163, Núm. 3, pp. 586-598

2020

  1. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database

    Arthritis research & therapy, Vol. 22, Núm. 1, pp. 257

  2. Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort

    Rheumatology (United Kingdom), Vol. 59, Núm. 8, pp. 2016-2023

  3. Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database

    Autoimmunity Reviews, Vol. 19, Núm. 2

  4. Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study

    Rheumatology (United Kingdom), Vol. 59, Núm. 7, pp. 1684-1694

2019

  1. Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis

    Arthritis and Rheumatology, Vol. 71, Núm. 9, pp. 1553-1570

2018

  1. Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study

    Arthritis and Rheumatology, Vol. 70, Núm. 11, pp. 1829-1834

  2. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study

    Rheumatology (United Kingdom), Vol. 57, Núm. 2, pp. 370-381

  3. Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study

    Annals of the Rheumatic Diseases, Vol. 77, Núm. 4, pp. 563-570

2017

  1. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 1, pp. 270-276

  2. Treatment outcome in early diffuse cutaneous systemic sclerosis: The European Scleroderma Observational Study (ESOS)

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 7, pp. 1207-1218

  3. Update of EULAR recommendations for the treatment of systemic sclerosis

    Annals of the Rheumatic Diseases, Vol. 76, Núm. 8, pp. 1327-1339

2016

  1. A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 1, pp. 163-169

  2. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: A 10-year longitudinal study from the EUSTAR database

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 7, pp. 1285-1292

  3. Incidences and risk factors of organ manifestations in the early course of systemic sclerosis: A longitudinal EUSTAR study

    PLoS ONE, Vol. 11, Núm. 10

  4. Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study

    Annals of the Rheumatic Diseases, Vol. 75, Núm. 1, pp. 103-109

2015

  1. Value of systolic pulmonary arterial pressure as a prognostic factor of death in the systemic sclerosis EUSTAR population

    Rheumatology (United Kingdom), Vol. 54, Núm. 7, pp. 1262-1269

2014

  1. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the international scleroderma renal crisis survey

    Seminars in Arthritis and Rheumatism, Vol. 43, Núm. 5, pp. 666-672

2011

  1. Is there a role for TNF-α antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique

    Clinical and Experimental Rheumatology, Vol. 29, Núm. 2 SUPPL. 65